Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic polymorphisms associated with glaucoma susceptibility and response to latanoprost
ChiCTR-OCC-11001326Phase 4Completed
- Sponsor
- Pharmacogenetics Research Institute, Xiangya Hospital, Central South University
- Start
- Apr 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of latanoprost in Glaucoma and ocular hypertension (2 arms), sponsored by Pharmacogenetics Research Institute, Xiangya Hospital, Central South University. Primary endpoint: Intraocular pressure. Started Apr 2011; status: completed.
02
Drugs
latanoprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on ChiCTR-OCC-11001326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCC-11001326.